Segment Disclosures

9 Months Ended

Sep. 30, 2014

Segment Reporting [Abstract]

Segment Disclosures

15. Segment Disclosures

We have aggregated our operations into two reportable segments based upon product lines, manufacturing processes, marketing and management of our businesses: medical equipment and radiopharmaceuticals.  Our business segments operate in the nuclear medicine industry. The Company’s medical equipment segment is currently generating all revenues and the majority of all expenses as the radiopharmaceuticals segment is still in the development phase.

We evaluate a segment’s performance based primarily upon operating income before corporate expenses.

Corporate assets consist primarily of cash but also include plant and equipment associated with our headquarters. These items (and income and expenses related to these items) are not allocated to the segments. Unallocated income/expenses include interest income, interest expense, debt extinguishment and refinancing costs and other (expense) income and certain expenses which are not considered related to either segment, but are instead considered general corporate expenses.

The following table represents sales, operating loss and total assets attributable to these business segments for the periods indicated (in thousands):

	Three Months Ended						Nine Months Ended
	September 30, 2014			September 30, 2013			September 30, 2014			September 30, 2013
Total Sales:
Medical equipment	$	391		$	351		$	1,202		$	1,154
Radiopharmaceuticals		5			-			5			-
Total sales	$	396		$	351		$	1,207		$	1,154
Operating loss:
Medical equipment	$	(600	)	$	(541	)	$	(1,628	)	$	(1,619	)
Radiopharmaceuticals		(107	)		(195	)		(471	)		(543	)
Total operating loss	$	(707	)	$	(736	)	$	(2,099	)	$	(2,162	)
Total Assets:
Medical equipment							$	2,172		$	1,596
Radiopharmaceuticals								448			882
Unallocated								-			-
Total Assets							$	2,620		$	2,478